Dow component Merck (NYSE:MRK) may be a juggernaut of the pharmaceutical industry, but there are plenty of reasons to be both bullish and bearish on this stock. In our brand new premium research report, our senior biotech analyst breaks down Merck's market opportunities, biggest threats, discusses the company's management, and offers compelling reasons to both buy and sell this stock.
Here is a small sample of what you'll find in the full report:
Three reasons to buy
- Merck is losing revenue from Singulair's patent expiration, but the company has a diversified portfolio that will help to mitigate this loss. Also, its diabetes drugs, Januvia and Janument, and HIV therapeutic Isentress displayed strong growth in recent quarters.
- The company is searching for additional blockbuster drugs -- and has the pipeline to prove it. Merck has several drugs in phase 2 and phase 3 clinical trials. Investors need to monitor the progress of these studies and hope that many make it through Food and Drug Administration approval.
- Merck's dividend yield, near the top of its peer group, can be attractive to long-term income investors.
We hope you enjoyed this sneak peek at our new premium research report on Merck. To get more in-depth information on this stock -- including an in-depth look at Merck's market opportunities -- click here today to learn more.
Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.